Candice Didychuk is the Manager of the Radiobiology & Health Branch at CNL, which encompasses the laboratories, facilities and the R&D teams in the areas of radiochemistry, medical isotope production & application, dosimetry & health risk, radiation biology and pre-clinical & toxicological research. Candice has been with CNL for >12 years, joining the Radiobiology and Health branch as an R&D scientist in January 2010. Her research focused on the pre-clinical evaluation of targeted radionuclide therapies, particularly new 225Ac drug conjugates for targeted alpha therapeutics of various types of cancer; and also the Biokinetic modelling and internal dosimetry of nuclear internal contamination hazards/radionuclides, such as nuclear fuels and actinides.
She served in the role of Section Head of Radiochemistry and Medical Applications at CNL for 4 years, managing several projects and commercial initiatives to drive and contribute support in the production of 225Ac and its application for targeted alpha therapy, and developing CNL’s preclinical R&D capabilities.
Her current goals are to advance expertise and capabilities in the defined research areas, while establishing new services, partnerships and collaborative research opportunities.